Osivax Partners with CEPI 

• Access to CEPI’s Adjuvant Library to assess dose-sparing potential of adjuvanted formulations of OVX836 vaccine in flu pandemic settings 

• Potential to maximize vaccine supply and broaden global access in emergencies, while maintaining a non-adjuvanted OVX836 core development path

 
Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses using its proprietary oligoDOM™ nanoparticle platform, today announced a partnership with the Coalition for Epidemic Preparedness Innovations (CEPI). Under this agreement, Osivax will access CEPI’s Adjuvant Library to investigate whether an adjuvanted formulation of OVX836, its broad-spectrum influenza A vaccine candidate, could enable dose-sparing in a pandemic response context.

The announcement was made today on the sidelines of the One Health Summit in Lyon, France, hosted by France under its G7 Presidency and coinciding with World Health Day.

OVX836 targets the highly conserved nucleoprotein (NP) of influenza A, including strains with pandemic or avian potential. By generating cross-reactive T-cell responses that act independently of surface antigen variation, OVX836 offers a strain-independent protection profile.

Read the press release